Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.

Fisher GA Jr, Wolin EM, Liyanage N, Lowenthal SP, Mirakhur B, Pommier RF, Shaheen M, Vinik AI; ELECT Study Investigators.

Endocr Pract. 2018 Mar;24(3):243-255. doi: 10.4158/EP172000.OR.

PMID:
29547049
2.

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA; ELECT Study Group *.

Endocr Pract. 2016 Sep;22(9):1068-80. doi: 10.4158/EP151172.OR. Epub 2016 May 23.

PMID:
27214300
3.

Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.

Fisher GA Jr, Wolin EM, Liyanage N, Pitman Lowenthal S, Mirakhur B, Pommier RF, Shaheen M, Vinik A; ELECT Study Group.

Oncologist. 2018 Jan;23(1):16-24. doi: 10.1634/theoncologist.2017-0284. Epub 2017 Oct 16.

4.

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, Blumberg J, Ruszniewski P.

Cancer. 2000 Feb 15;88(4):770-6.

PMID:
10679645
5.

An update of lanreotide acetate for treatment of adults with carcinoid syndrome.

Guadalupe E, Deshpande HA, Stein SM.

Drugs Today (Barc). 2018 Aug;54(8):457-465. doi: 10.1358/dot.2018.54.8.2834461. Review.

PMID:
30209440
6.

Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.

Ruszniewski P, Valle JW, Lombard-Bohas C, Cuthbertson DJ, Perros P, Holubec L, Delle Fave G, Smith D, Niccoli P, Maisonobe P, Atlan P, Caplin ME; SYMNET study group.

Dig Liver Dis. 2016 May;48(5):552-558. doi: 10.1016/j.dld.2015.12.013. Epub 2016 Jan 15.

7.

Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.

Raderer M, Kurtaran A, Scheithauer W, Fiebiger W, Weinlaender G, Oberhuber G.

Oncology. 2001;60(2):141-5.

PMID:
11244329
8.

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.

Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A; Pasireotide C2402 Study Group.

Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84. doi: 10.1016/S2213-8587(14)70169-X. Epub 2014 Sep 24.

PMID:
25260838
9.

Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.

Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G, Roncella M, Mosca F, Conte PF.

Am J Clin Oncol. 2000 Aug;23(4):412-5.

PMID:
10955874
10.

Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.

Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF.

Ann Oncol. 2000 Sep;11(9):1127-30.

PMID:
11061606
11.

Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).

Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME.

Aliment Pharmacol Ther. 2011 Jul;34(2):235-42. doi: 10.1111/j.1365-2036.2011.04693.x. Epub 2011 May 17.

12.
13.

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.

Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K.

Drug Des Devel Ther. 2015 Sep 3;9:5075-86. doi: 10.2147/DDDT.S84177. eCollection 2015.

14.

INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.

Tadman M, Charlton P, Jafar-Mohammadi B, Talbot D, Grossman AB.

Endocr Pract. 2018 Feb;24(2):189-194. doi: 10.4158/EP-2017-0137.

PMID:
29466059
15.

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators.

N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158.

16.

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.

Ruszniewski P, Ish-Shalom S, Wymenga M, O'Toole D, Arnold R, Tomassetti P, Bax N, Caplin M, Eriksson B, Glaser B, Ducreux M, Lombard-Bohas C, de Herder WW, Delle Fave G, Reed N, Seitz JF, Van Cutsem E, Grossman A, Rougier P, Schmidt W, Wiedenmann B.

Neuroendocrinology. 2004;80(4):244-51. Epub 2004 Dec 22.

PMID:
15627802
17.

Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.

Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

Oncologist. 2014 Sep;19(9):930-6. doi: 10.1634/theoncologist.2014-0120. Epub 2014 Aug 5.

18.

Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.

Pokuri VK, Fong MK, Iyer R.

Curr Oncol Rep. 2016 Jan;18(1):7. doi: 10.1007/s11912-015-0492-7. Review.

PMID:
26743514
19.

Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.

Wolin EM, Manon A, Chassaing C, Lewis A, Bertocchi L, Richard J, Phan AT.

J Gastrointest Cancer. 2016 Dec;47(4):366-374. Review.

20.

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.

Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Öberg K, Pavel ME.

Endocr Relat Cancer. 2015 Dec;22(6):933-40. doi: 10.1530/ERC-15-0314. Epub 2015 Sep 15.

Supplemental Content

Support Center